Outliers of Treatment Frequency in Retinal Vein Occlusion: 24‐Month Comparative Analysis of Fight Retinal Blindness! Practitioners
At 24 months, the intensive practitioners were treating RVO using VEGF inhibitors with twice the frequency of the relaxed practitioners; however, their patients had gained twice (BRVO) to three times (CRVO) more letters of VA.
Authors
- Louise O’Toole (ORCID: https://orcid.org/0000-0003-4851-0918)
- Adrian Hunt (ORCID: https://orcid.org/0000-0002-6261-4679)
- Alessandro Invernizzi (ORCID: https://orcid.org/0000-0003-3400-1987)
- Hemal Mehta (ORCID: https://orcid.org/0000-0002-0606-9004)
- Rufino Silva (ORCID: https://orcid.org/0000-0001-8676-0833)
- Francisco Javier Lavid (ORCID: https://orcid.org/0000-0003-4229-8565)
- Yohei Hashimoto (ORCID: https://orcid.org/0000-0002-7944-6923)
- Nandor Jaross
- Pierre‐Henry Gabrielle (ORCID: https://orcid.org/0000-0002-9688-4845)
- David Squirrell (ORCID: https://orcid.org/0000-0002-8393-7100)
- Daniel Barthelmes (ORCID: https://orcid.org/0000-0002-5431-4991)
- Theodorus Leonardus Ponsioen (ORCID: https://orcid.org/0000-0002-1414-836X)
- Pavol Kusenda (ORCID: https://orcid.org/0009-0007-3049-8304)
- Mark C. Gillies
Institutions
- The University of Sydney (AU)
- Royal Free London NHS Foundation Trust (GB)
- University of Milan (IT)
- University of Zurich (CH)
- Vision Australia (AU)
- Westmead Hospital (AU)
- Mater Misericordiae University Hospital (IE)
- Luigi Sacco Hospital (IT)
- University Hospital Bratislava (SK)
- University Hospital of Zurich (CH)
- Auckland District Health Board (NZ)
- Association for Innovation and Biomedical Research on Light and Image (PT)
- Maison des Sciences sociales et des Humanités de Dijon (FR)
- Isala (NL)
- Comenius University Bratislava (SK)
- University of Coimbra (PT)
Publication Details
- Journal
- Clinical and Experimental Ophthalmology
- Published
- 2024-12-28
- DOI
- https://doi.org/10.1111/ceo.14490
- Citations
- 2
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.08
Funders
- Novartis Pharmaceuticals Corporation
- Ögonfonden
- Royal Australian and New Zealand College of Ophthalmologists
- Bayer Foundation
- Medical Research Council
- National Health and Medical Research Council